Rachelle Jacques appointed CEO of Akari Therapeutics

Friday 4 March 2022
Akari Therapeutics Plc
Appointee name
Rachelle Jacques

United Kingdom

Rachelle Jacques has been appointed chief executive of Akari Therapeutics Plc, effective at the end of March, to advance the company’s Phase 3 drug pipeline through registration and onto the market. Akari is developing medicines for rare and orphan diseases. Ms Jacques was previously CEO of Enzyvant Therapeutics Inc, which is developing regenerative therapies for rare diseases. Prior to this, she was an executive at Alexion Pharmaceuticals Inc, now part of AstraZeneca Plc, where she led the company’s franchise in complement inhibitors.

In addition to her corporate responsibilities, Ms Jacques is co-chair of the Alliance for Regenerative Medicine’s tissue engineering and biomaterials committee. She received a bachelor degree in business administration from Alma College in Michigan, US.

Akari Therapeutics announced the appointments on 2 March 2022.

Copyright 2022 Evernow Publishing Ltd